Recent Updates
Recently added Catalysts
GKOS Positive Sentiment Score: 85/100

Glaukos Announces Second Quarter 2026 Financial Results

Wednesday, July 29, 2026 1 min read
Key Takeaway: Glaukos Corporation reported impressive financial results for Q2 2026, achieving record net sales of $185.6 million. This marks a 50% increase compared to the same period last year. The company also noted a 49% rise in sales on a constant currency basis, highlighting its strong market position in ophthalmic therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Record net sales of $185.6 million in Q2 2026.
  • Sales increased by 50% year-over-year.
  • Strong performance on a constant currency basis.

Full Press Release Details

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include: Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record ne

Frequently Asked Questions

What were Glaukos' net sales in Q2 2026?

Glaukos reported net sales of $185.6 million in Q2 2026.

How much did Glaukos' sales increase year-over-year?

Sales increased by 50% year-over-year in Q2 2026.

What was the constant currency sales increase for Glaukos?

The sales increase on a constant currency basis was 49%.

Tags: GKOS Viatris Investor Conferences Healthcare Glaukos financial results Q2 2026 ophthalmic therapies
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$277M liquidity · $4M/mo burn
~63 mo
Minimal dilution risk
Lead asset
Gen 2 Travoprost IntracameralPhase 3
Glaucoma →

Catalyst track record

+66%
best trade around GKOS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for GKOS.

See every catalyst's timing & PoA →